Abiomed (NASDAQ: ABMD) announces the results of PROTECT III, the ongoing, prospective, single-arm FDA post-approval study for the PMA approval of Impella 2.5 and Impella CP in high-risk PCI. PROTECT ...
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces the United States Food and Drug Administration (FDA) has approved the company's investigational device exemption application to start ...
For some patients, a percutaneous left ventricular assist device (LVAD) may increase the risk of subsequent aortic regurgitation (AR), especially when there’s a need for longer support, new data ...
DANVERS, Mass.--(BUSINESS WIRE)--The United States Food and Drug Administration (FDA) has granted breakthrough device designation to Abiomed’s (NASDAQ: ABMD) Impella ECP expandable percutaneous heart ...
The manufacturer has identified that certain Abiomed heart pumps with differential pressure sensors have the potential to display inaccurate information.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results